公开(公告)号：US20190070137A1

公开(公告)日：2019-03-07

申请号：US16166272

申请日：2018-10-22

Applicant: Infirst Healthcare Limited

Inventor： Robin M. Bannister ,  John Brew ,  Richard R. Reiley, III ,  Wilson Caparros Wanderley

IPC: A61K31/192 ,  A61K47/44 ,  A61K47/22 ,  A61K9/08 ,  A61K9/20 ,  A61K31/12 ,  A61K31/121 ,  A61K31/196 ,  A61K47/14 ,  A61K47/10 ,  A61K31/616 ,  A61K31/60 ,  A61K31/201 ,  A61K31/202 ,  A61K31/704 ,  A61K31/25 ,  A61K31/337

CPC classification number: A61K31/192 ,  A61K9/08 ,  A61K9/2013 ,  A61K31/12 ,  A61K31/121 ,  A61K31/196 ,  A61K31/201 ,  A61K31/202 ,  A61K31/25 ,  A61K31/337 ,  A61K31/60 ,  A61K31/616 ,  A61K31/704 ,  A61K47/10 ,  A61K47/14 ,  A61K47/22 ,  A61K47/44 ,  Y02A50/411

Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

公开(公告)号：US20190023682A1

公开(公告)日：2019-01-24

申请号：US15782002

申请日：2016-12-09

Applicant: Rutgers, The State University of New Jersey

Inventor： Richard H. Ebright ,  Joel Freundlich ,  Nisha Mittal ,  Mark Jaskowski ,  Juan Shen

IPC: C07D333/22 ,  C07C49/83 ,  C07C49/84 ,  C07D213/643 ,  A61P31/04

CPC classification number: C07D333/22 ,  A61K31/12 ,  A61K31/381 ,  A61P31/04 ,  C07C49/753 ,  C07C49/83 ,  C07C49/835 ,  C07C49/84 ,  C07C2601/02 ,  C07C2601/16 ,  C07D213/64 ,  C07D213/643

Abstract: The invention provides compounds that are inhibitors of bacterial RNA polymerase. The invention also provides compositions comprising such compounds, methods of making such compounds, and methods of using said compounds. The invention has applications in control of bacterial gene expression, control of bacterial growth, antibacterial chemistry, and antibacterial therapy.

公开(公告)号：US20180360828A9

公开(公告)日：2018-12-20

申请号：US15884044

申请日：2018-01-30

Applicant: Aquinox Pharmaceuticals (Canada) Inc.

Inventor： Lloyd F. Mackenzie ,  Thomas B. MacRury ,  Curtis Harwig ,  David Bogucki ,  Jeffery R. Raymond ,  Jeremy D. Pettigrew ,  Vladimir Khlebnikov ,  Rudong Shan

IPC: A61K31/4965 ,  A61K31/496 ,  A61K31/444 ,  A61K31/443 ,  A61K31/10 ,  A61K31/4465 ,  A61K31/4406 ,  A61K31/155 ,  A61K31/495 ,  A61K31/4196 ,  A61K31/4164 ,  A61K31/4402 ,  A61K31/166 ,  A61K31/095 ,  A61K31/277 ,  A61K31/165 ,  A61K31/167 ,  A61K31/09 ,  A61K31/192 ,  A61K31/05 ,  A61K31/085 ,  A61K31/135 ,  A61K31/122 ,  A61K31/12 ,  A61K31/4439

CPC classification number: A61K31/4965 ,  A61K31/05 ,  A61K31/085 ,  A61K31/09 ,  A61K31/095 ,  A61K31/10 ,  A61K31/12 ,  A61K31/122 ,  A61K31/135 ,  A61K31/155 ,  A61K31/165 ,  A61K31/166 ,  A61K31/167 ,  A61K31/192 ,  A61K31/277 ,  A61K31/4164 ,  A61K31/4196 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4465 ,  A61K31/495 ,  A61K31/496 ,  C07B2200/07 ,  C07C39/17 ,  C07C43/21 ,  C07C43/215 ,  C07C43/23 ,  C07C49/83 ,  C07C49/835 ,  C07C49/84 ,  C07C62/32 ,  C07C62/34 ,  C07C217/84 ,  C07C225/20 ,  C07C233/26 ,  C07C233/28 ,  C07C233/31 ,  C07C233/32 ,  C07C233/60 ,  C07C233/76 ,  C07C235/82 ,  C07C237/08 ,  C07C255/47 ,  C07C275/26 ,  C07C275/64 ,  C07C279/16 ,  C07C311/07 ,  C07C311/17 ,  C07C311/18 ,  C07C317/22 ,  C07C323/20 ,  C07C2602/28 ,  C07D211/66 ,  C07D213/38 ,  C07D213/75 ,  C07D213/81 ,  C07D213/82 ,  C07D213/89 ,  C07D233/64 ,  C07D241/24 ,  C07D249/08 ,  C07D295/112 ,  C07D295/215 ,  C07D401/12 ,  C07D405/12

Abstract: Compounds of formula (I): where n, R1, R4a, R4b, R5, R7 and R8 are defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.

公开(公告)号：US20180344856A1

公开(公告)日：2018-12-06

申请号：US16100246

申请日：2018-08-10

Applicant: The Procter & Gamble Company

Inventor： Paul Robert Tanner ,  Larry Richard Robinson

IPC: A61K47/14 ,  A61Q19/00 ,  A61K8/02 ,  A61K8/49 ,  A61K31/05 ,  A61K31/352 ,  A61K31/12

CPC classification number: A61K47/14 ,  A61K8/0208 ,  A61K8/4973 ,  A61K31/05 ,  A61K31/12 ,  A61K31/352 ,  A61Q19/005

Abstract: Personal care compositions for use in an absorbent article are disclosed comprising an isosorbide diester having the formula: wherein R′ and R″ are independently selected from a straight or branched C1-30 chain, which may be saturated or unsaturated. The personal care compositions also comprise a solid cosmetic active soluble in the isosorbide diester and a dermatologically acceptable carrier. The personal care composition may be in the form of an emulsion. A personal care composition is also disclosed comprising an isosorbide diester having the formula: wherein R′ and R″ are independently selected from a straight or branched C1-30 chain which may be saturated or unsaturated and Z1-Z6 are independently selected from hydrogen, hydroxyl, amino, amido, R′, or R″. Methods of making the aforementioned personal care compositions are also disclosed.

公开(公告)号：US20180344680A1

公开(公告)日：2018-12-06

申请号：US16060742

申请日：2016-12-07

Applicant: THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA

Inventor： Donna D. Zhang ,  Georg T. Wondrak

IPC: A61K31/26 ,  A61K31/11 ,  A61P17/02 ,  A61K31/522 ,  A61K31/4709 ,  A61K31/4365 ,  A61K31/235 ,  A61K38/18

CPC classification number: G01N33/6872 ,  A61K9/0014 ,  A61K31/05 ,  A61K31/11 ,  A61K31/12 ,  A61K31/192 ,  A61K31/232 ,  A61K31/26 ,  A61K31/277 ,  A61K31/343 ,  A61K31/4365 ,  A61K31/4709 ,  A61K31/522 ,  A61K31/616 ,  A61K38/00 ,  A61K2300/00

Abstract: Compositions and methods are provided for treating, ameliorating, and preventing diabetes-related skin ulcers in a mammalian subject comprising administering to the subject an effective amount of an NRF2 activating agent.

公开(公告)号：US20180333388A1

公开(公告)日：2018-11-22

申请号：US15936695

申请日：2018-03-27

Applicant: Caliway Biopharmaceuticals Co., Ltd.

Inventor： YU-FANG LING

IPC: A61K31/353 ,  A23F3/16 ,  A61K45/06 ,  A61K36/82 ,  A23L33/105 ,  A61K31/12 ,  A61K31/4184 ,  A61K36/9066

CPC classification number: A61K31/353 ,  A23F3/16 ,  A23L33/105 ,  A23V2002/00 ,  A61K31/12 ,  A61K31/4184 ,  A61K36/82 ,  A61K36/9066 ,  A61K45/06 ,  A61K2300/00 ,  A23V2200/328 ,  A23V2200/332

Abstract: The present invention discloses a composition and its pharmaceutical composition for reducing body weight and body fat, and a use of said product The composition comprises epigallocatechin gallate, curcumin, and an excipient, wherein the excipient comprises at least one of glyceryl dibehenate, polyoxyethylene stearates, polysorbate 80 mixture, vitamin E polyethylene glycol succinate, glyceryl monostearate, and oleoyl polyoxyl-6 glycerides, or a combination thereof; the polysorbate 80 mixture comprises polysorbate 80 and magnesium aluminometasilicate. In animal testing where obesity is induced either prior to or during testing, use of the composition of the present invention leads to a significant reduction of body weight and body fat.

公开(公告)号：US20180325841A1

公开(公告)日：2018-11-15

申请号：US15777529

申请日：2016-11-18

Applicant: DANKOOK UNIVERSITY CHEONAN CAMPUS INDUSTRY ACADEMIC COOPERATION FOUNDATION

Inventor： So-Young PARK ,  Hwan-Bin JOO

IPC: A61K31/12 ,  A61K36/11 ,  A61K31/473 ,  A61K31/445 ,  A61K31/27 ,  A61K31/55

CPC classification number: A61K31/12 ,  A61K9/20 ,  A61K9/48 ,  A61K31/045 ,  A61K31/05 ,  A61K31/27 ,  A61K31/445 ,  A61K31/473 ,  A61K31/55 ,  A61K36/11 ,  A61K36/12

Abstract: The present disclosure relates to a use of a phloroglucinol-based compound and its salt for preventing and treating Alzheimer's disease. The pharmaceutical composition for preventing or treating Alzheimer's disease of the present disclosure fundamentally suppresses the cause of β-amyloid formation, thereby exerting a remarkable effect of allowing ultimate treatment of Alzheimer's disease. The present disclosure provides the use of the single substance, which has been isolated from Dryopteris crassirhizoma and identified, for preventing or treating Alzheimer's disease for the first time.

公开(公告)号：US20180303955A1

公开(公告)日：2018-10-25

申请号：US15769586

申请日：2016-10-21

Applicant: IMMIX BIOPHARMA, INC

Inventor： Ilya Rachman

IPC: A61K47/69 ,  A61K47/68 ,  A61K31/12 ,  A61K31/704 ,  A61K9/00 ,  A61P35/00

CPC classification number: A61K47/6909 ,  A61K9/0019 ,  A61K9/1075 ,  A61K31/12 ,  A61K31/704 ,  A61K39/395 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6849 ,  A61K2039/505 ,  A61K2039/55 ,  A61P35/00 ,  C07K16/28 ,  C07K2317/622

Abstract: Disclosed herein are compositions and nanoconjugates comprising a micelle construct; an antibody single chain fragment variable (scFv); a NF-kb inhibitor; and a topoisomerase II inhibitor. Further disclosed herein are methods of delivering a drug molecule to a tumor site of a subject comprising: attaching the drug molecule to a targeted micelle, wherein the targeted micelle comprises a micelle construct and an antibody single chain fragment variable (scFv); and delivering the drug molecule attached to the targeted micelle to the tumor site through intracellular delivery. Also disclosed herein are methods of treating cancer or inhibiting tumor cell growth comprising administering to a subject in need thereof, a therapeutically effective dosage of a composition comprising a micelle construct, an antibody single chain fragment variable (say), a NF-kb inhibitor, and a topoisomerase II inhibitor.

公开(公告)号：US20180263917A1

公开(公告)日：2018-09-20

申请号：US15987455

申请日：2018-05-23

Applicant: Darren Rubin

Inventor： Darren Rubin

IPC: A61K9/48 ,  A61K9/00 ,  A61K9/28 ,  A61K31/4439 ,  A61K31/496 ,  A61K31/7048 ,  A61K31/7052 ,  A61K31/706 ,  A61K31/7034 ,  A61K31/43 ,  A61K31/431 ,  A61K45/06 ,  A61K31/47 ,  A61K31/4164 ,  A61K31/65 ,  A61K31/341 ,  A61K31/425 ,  A61K31/616 ,  A61K31/192 ,  A61K31/196 ,  A61K31/407 ,  A61K31/421 ,  A61K31/5415 ,  A61K31/40 ,  A61K31/415 ,  A61K31/405 ,  A61K31/12 ,  A61K31/235

CPC classification number: A61K9/4891 ,  A61K9/0053 ,  A61K9/28 ,  A61K9/2886 ,  A61K9/4808 ,  A61K31/12 ,  A61K31/192 ,  A61K31/196 ,  A61K31/235 ,  A61K31/341 ,  A61K31/40 ,  A61K31/405 ,  A61K31/407 ,  A61K31/415 ,  A61K31/4164 ,  A61K31/421 ,  A61K31/425 ,  A61K31/43 ,  A61K31/431 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/496 ,  A61K31/5415 ,  A61K31/616 ,  A61K31/65 ,  A61K31/7034 ,  A61K31/7048 ,  A61K31/7052 ,  A61K31/706 ,  A61K45/06 ,  A61P1/04

Abstract: Methods are for the preparation and medicinal use of pharmaceutical formulations for the treatment of bacterial infection and/or duodenal ulcer disease.

公开(公告)号：US20180235928A1

公开(公告)日：2018-08-23

申请号：US15754133

申请日：2016-08-18

Applicant: The Methodist Hospital

Inventor： Ren Kong ,  Hong Zhao ,  Stephen T.C. Wong

IPC: A61K31/352 ,  A61K45/06 ,  A61K31/4745 ,  A61K9/00 ,  A61K31/12 ,  A61P1/12

CPC classification number: A61K31/352 ,  A61K9/0053 ,  A61K31/12 ,  A61K31/121 ,  A61K31/353 ,  A61K31/4745 ,  A61K45/06 ,  A61P1/12 ,  A61K2300/00

Abstract: A method for treating diarrhea induced by a chemotherapy agent by administering a carboxylesterase 2 (CES2) inhibitor, i.e., hesperetin, naringenin, or 2′,4′-dihydroxychalcone. Also disclosed is a method for treating cancer by administering a chemotherapy agent together with hesperetin, naringenin, or 2′,4′-dihydroxychalcone. Furthermore, a composition for treating cancer is provided, the composition containing a chemotherapy agent and hesperetin, naringenin, or 2′,4′-dihydroxychalcone.